Abstract
Lung cancer comprises of two major clinically relevant types, non-small cell lung cancer (NSCLC) representing about 85% of all cases and small cell lung cancer (SCLC) accounting for the remaining 15%. Despite recent advancements that include new understanding of the molecular mechanisms involved in cancer pathogenesis and introduction of new treatments, lung cancer continues to reign as the leading cause of cancer deaths worldwide. Innovations in genomics-based technologies are becoming rapidly integrated into lung cancer research and the results of these efforts have started to yield tangible advances in improved understanding and treatment of lung cancer.
Original language | English |
---|---|
Pages (from-to) | 313-322 |
Number of pages | 10 |
Journal | Current Respiratory Medicine Reviews |
Volume | 7 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2011 Oct 1 |
Externally published | Yes |
Keywords
- Biomarkers
- Cancer stem cell
- Cancer-associated fibroblasts
- Genomics
- Lung cancer
- Oncogene
- Personalized medicine
- Stroma
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine